Generation and characterization of the humoral immune response to DNA immunization with a chimeric β-amyloid-interleukin-4 minigene

被引:58
作者
Ghochikyan, A
Vasilevko, V
Petrushina, I
Movsesyan, N
Babikyan, D
Tian, WQ
Sadzikava, N
Ross, TM
Head, E
Cribbs, DH
Agadjanyan, MG
机构
[1] Inst Mol Med, Dept Immunol, Huntington Beach, CA 92647 USA
[2] E Carolina Univ, Sch Med, Dept Microbiol & Immunol, Greenville, NC 27858 USA
[3] Univ Calif Irvine, Dept Mol Biol & Biochem, Irvine, CA 92717 USA
[4] Univ Calif Irvine, Inst Brain Aging & Dementia, Irvine, CA USA
关键词
DNA immunization; antibodies; epitopes; mice; antigens;
D O I
10.1002/eji.200324000
中图分类号
R392 [医学免疫学]; Q939.91 [免疫学];
学科分类号
100102 ;
摘要
Active immunization with fibrillar beta-amyloid peptide (Abeta(42)) as well as passive transfer of anti-Abeta antibodies significantly reduces Abeta plaque deposition, neuritic dystrophy, and astrogliosis in the brain of mutant amyloid precursor protein (APP)-transgenic mice. Although the mechanism(s) of clearance of Abeta from the brain following active or passive immunization remains to be determined, it is clear that anti-Abeta antibodies are critical for clearance. DNA immunization provides an attractive alternative to direct peptide and adjuvant approaches for inducing a humoral response to Abeta. We constructed a DNA minigene with Abeta fused to mouse interleukin-4 (pAbeta(42)-IL-4) as a molecular adjuvant to generate anti-Abeta antibodies and enhance the Th2-type of immune responses. Gene gun immunizations induced primarily IgG1 and IgG2b anti-Abeta antibodies. Fine epitope analysis with overlapping peptides of the Abeta(42) sequence identified the 1-15 region as a dominant B cell epitope. The DNA minigene-induced anti-Abeta antibodies bound to Abeta plaques in brain tissue from an Alzheimer's disease patient demonstrating functional activity of the antibodies and the potential for therapeutic efficacy.
引用
收藏
页码:3232 / 3241
页数:10
相关论文
共 61 条
[1]  
AGADJANYAN MG, 1994, VACCINES 94 - MODERN APPROACHES TO NEW VACCINES INCLUDING PREVENTION OF AIDS, P47
[2]  
Agadjanyan MG, 1999, J IMMUNOL, V162, P3417
[3]   An HIV type 2 DNA vaccine induces cross-reactive immune responses against HIV type 2 and SIV [J].
Agadjanyan, MG ;
Trivedi, NN ;
Kudchodkar, S ;
Bennet, M ;
Levine, W ;
Lin, A ;
Boyer, J ;
Levy, D ;
Ugen, KE ;
Kim, JJ ;
Weiner, DB .
AIDS RESEARCH AND HUMAN RETROVIRUSES, 1997, 13 (18) :1561-1572
[4]   Peripherally administered antibodies against amyloid β-peptide enter the central nervous system and reduce pathology in a mouse model of Alzheimer disease [J].
Bard, F ;
Cannon, C ;
Barbour, R ;
Burke, RL ;
Games, D ;
Grajeda, H ;
Guido, T ;
Hu, K ;
Huang, JP ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, M ;
Lieberburg, I ;
Motter, R ;
Nguyen, M ;
Soriano, F ;
Vasquez, N ;
Weiss, K ;
Welch, B ;
Seubert, P ;
Schenk, D ;
Yednock, T .
NATURE MEDICINE, 2000, 6 (08) :916-919
[5]   Epitope and isotype specificities of antibodies to β-amyloid peptide for protection against Alzheimer's disease-like neuropathology [J].
Bard, F ;
Barbour, R ;
Cannon, C ;
Carretto, R ;
Fox, M ;
Games, D ;
Guido, T ;
Hoenow, K ;
Hu, K ;
Johnson-Wood, K ;
Khan, K ;
Kholodenko, D ;
Lee, C ;
Lee, M ;
Motter, R ;
Nguyen, M ;
Reed, A ;
Schenk, D ;
Tang, P ;
Vasquez, N ;
Seubert, P ;
Yednock, T .
PROCEEDINGS OF THE NATIONAL ACADEMY OF SCIENCES OF THE UNITED STATES OF AMERICA, 2003, 100 (04) :2023-2028
[6]   Strategies for designing and optimizing new generation vaccines [J].
Berzofsky, JA ;
Ahlers, JD ;
Belyakov, IM .
NATURE REVIEWS IMMUNOLOGY, 2001, 1 (03) :209-219
[7]   Set back to Alzheimer vaccine studies [J].
Birmingham, K ;
Frantz, S .
NATURE MEDICINE, 2002, 8 (03) :199-200
[8]   Amyloid immunotherapy-engendered CNS inflammation [J].
Bowers, WJ ;
Federoff, HJ .
NEUROBIOLOGY OF AGING, 2002, 23 (05) :675-676
[9]   A learning deficit related to age and β-amyloid plaques in a mouse model of Alzheimer's disease [J].
Chen, GQ ;
Chen, KS ;
Knox, J ;
Inglis, J ;
Bernard, A ;
Martin, SJ ;
Justice, A ;
McConlogue, L ;
Games, D ;
Freedman, SB ;
Morris, RGM .
NATURE, 2000, 408 (6815) :975-979
[10]  
Chow YH, 1998, J IMMUNOL, V160, P1320